Sight Sciences, Inc. (NASDAQ:SGHT – Get Free Report) EVP Brenton Taylor sold 2,829 shares of Sight Sciences stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $5.42, for a total value of $15,333.18. Following the sale, the executive vice president directly owned 264,978 shares of the company’s stock, valued at approximately $1,436,180.76. This trade represents a 1.06% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Sight Sciences Trading Down 2.4%
NASDAQ:SGHT opened at $5.35 on Wednesday. The firm has a 50-day simple moving average of $4.97 and a 200-day simple moving average of $5.29. Sight Sciences, Inc. has a one year low of $3.11 and a one year high of $9.24. The firm has a market cap of $291.09 million, a P/E ratio of -7.54 and a beta of 2.38. The company has a debt-to-equity ratio of 0.68, a quick ratio of 5.48 and a current ratio of 5.86.
Sight Sciences (NASDAQ:SGHT – Get Free Report) last issued its quarterly earnings data on Wednesday, May 6th. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.05). The company had revenue of $19.70 million for the quarter, compared to the consensus estimate of $18.46 million. Sight Sciences had a negative net margin of 46.83% and a negative return on equity of 52.34%. Equities analysts anticipate that Sight Sciences, Inc. will post -0.6 EPS for the current fiscal year.
Sight Sciences News Summary
- Negative Sentiment: CEO Paul Badawi sold 28,684 shares, the largest disclosed insider transaction in the batch, which may suggest reduced insider confidence. Sight Sciences (NASDAQ:SGHT) CEO Paul Badawi Sells 28,684 Shares of Stock
- Negative Sentiment: CFO James Rodberg sold 6,902 shares, adding to the leadership-level selling pressure. Sight Sciences (NASDAQ:SGHT) CFO Sells 6,902 Shares
- Negative Sentiment: CTO David Badawi, EVP Brenton Taylor, and insider Jeremy B. Hayden also sold shares, reinforcing the pattern of insider reductions across the company. Insider Selling: Sight Sciences (NASDAQ:SGHT) CTO Sells $40,873.18 in Stock Sight Sciences (NASDAQ:SGHT) EVP Sells $15,333.18 in Stock
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. BNP Paribas Financial Markets lifted its stake in shares of Sight Sciences by 99.8% in the third quarter. BNP Paribas Financial Markets now owns 7,579 shares of the company’s stock worth $26,000 after buying an additional 3,785 shares in the last quarter. Tower Research Capital LLC TRC grew its stake in Sight Sciences by 32.7% during the 2nd quarter. Tower Research Capital LLC TRC now owns 11,665 shares of the company’s stock valued at $48,000 after acquiring an additional 2,875 shares in the last quarter. Diversified Trust Co purchased a new stake in Sight Sciences during the 1st quarter valued at about $51,000. XTX Topco Ltd acquired a new stake in Sight Sciences in the 2nd quarter valued at about $67,000. Finally, O Shaughnessy Asset Management LLC purchased a new position in Sight Sciences in the 4th quarter worth approximately $81,000. 55.51% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
SGHT has been the topic of several research reports. Citigroup increased their price target on shares of Sight Sciences from $4.35 to $5.15 and gave the stock a “neutral” rating in a report on Thursday, May 28th. Weiss Ratings lowered shares of Sight Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, May 11th. Five research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $8.14.
Get Our Latest Research Report on Sight Sciences
About Sight Sciences
Sight Sciences, Inc is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company’s flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye’s natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy.
Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model.
See Also
- Five stocks we like better than Sight Sciences
- Apple and Broadcom Forge a Decade-Long Silicon Fortress
- SK Hynix’s Nasdaq Listing Could Reset the AI Memory Trade
- The AI Chip Sell-Off Looks Scary, But the Real Story May Be Liquidity
- Palantir’s CEO Just Called Out OpenAI and Anthropic
Receive News & Ratings for Sight Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sight Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
